When it comes to detecting disease and understanding how the body works, protein research has long been overshadowed by DNA sequencing.
But the field, known as proteomics, has seen a surge of activity in recent months. Larger players have struck billion-dollar-plus deals, a proposed $1.4 billion international collaboration has launched, and new research has shown that a proteomics cancer diagnostic might challenge some of the DNA-based players that currently dominate that field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.